SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.+539.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SAVA vs AVXL
Revenue, margins, valuation, and 5-year total return — side by side.
AVXL
Anavex Life Sciences Corp.
Biotechnology
Market Cap$289M
5Y Perf.+7.8%
SAVA vs AVXL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SAVA | AVXL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $94M | $289M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-106M | $-40M |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $129M | $103M |
SAVA vs AVXL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SAVA
AVXL
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Cassava Sciences, I… (SAVA) | 100 | 639.5 | +539.5% |
| Anavex Life Science… (AVXL) | 100 | 107.8 | +7.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SAVA vs AVXL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AVXL leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Cassava Sciences, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SAVA
Cassava Sciences, Inc.
The Growth Play
SAVA is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 77.6%
- -19.5% 10Y total return vs AVXL's -25.7%
- 5.4% margin vs AVXL's 4.5%
Best for: growth exposure and long-term compounding
AVXL
Anavex Life Sciences Corp.
The Income Pick
AVXL carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.51
- Lower volatility, beta 1.51, current ratio 11.60x
- Beta 1.51, current ratio 11.60x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AVXL | -34.9% revenue growth vs SAVA's -5.4% |
| Quality / Margins | SAVA | 5.4% margin vs AVXL's 4.5% |
| Stability / Safety | AVXL | Beta 1.51 vs SAVA's 2.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SAVA | +25.3% vs AVXL's -63.2% |
| Efficiency (ROA) | AVXL | -30.0% ROA vs SAVA's -75.3% |
SAVA vs AVXL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSAVALAGGINGAVXL
AVXLAnavex Life Sciences …
1leads
SAVACassava Sciences, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs AVXLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AVXL3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
SAVA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SAVA and AVXL operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SAVACassava Sciences,… | AVXLAnavex Life Scien… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$110M | -$30M |
| Net IncomeAfter-tax profit | -$106M | -$40M |
| Free Cash FlowCash after capex | -$84M | -$34M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +62.1% | +54.4% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SAVA and AVXL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SAVACassava Sciences,… | AVXLAnavex Life Scien… |
|---|---|---|
| Market CapShares × price | $94M | $289M |
| Enterprise ValueMkt cap + debt − cash | -$34M | $187M |
| Trailing P/EPrice ÷ TTM EPS | -3.76x | -5.78x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.63x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SAVA and AVXL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
AVXL leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
AVXL delivers a -31.5% return on equity — every $100 of shareholder capital generates $-32 in annual profit, vs $-96 for SAVA.
| Metric | SAVACassava Sciences,… | AVXLAnavex Life Scien… |
|---|---|---|
| ROE (TTM)Return on equity | -95.8% | -31.5% |
| ROA (TTM)Return on assets | -75.3% | -30.0% |
| ROICReturn on invested capital | -6.3% | — |
| ROCEReturn on capital employed | -99.9% | -47.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$129M | -$103M |
| Cash & Equiv.Liquid assets | $129M | $103M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
AVXL leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
SAVA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SAVA five years ago would be worth $3,302 today (with dividends reinvested), compared to $2,759 for AVXL. Over the past 12 months, SAVA leads with a +25.3% total return vs AVXL's -63.2%. The 3-year compound annual growth rate (CAGR) favors SAVA at -16.0% vs AVXL's -28.1% — a key indicator of consistent wealth creation.
| Metric | SAVACassava Sciences,… | AVXLAnavex Life Scien… |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | -15.2% |
| 1-Year ReturnPast 12 months | +25.3% | -63.2% |
| 3-Year ReturnCumulative with dividends | -40.8% | -62.9% |
| 5-Year ReturnCumulative with dividends | -67.0% | -72.4% |
| 10-Year ReturnCumulative with dividends | -19.5% | -25.7% |
| CAGR (3Y)Annualised 3-year return | -16.0% | -28.1% |
SAVA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SAVA and AVXL each lead in 1 of 2 comparable metrics.
Risk & Volatility
AVXL is the less volatile stock with a 1.51 beta — it tends to amplify market swings less than SAVA's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SAVA currently trades 39.3% from its 52-week high vs AVXL's 22.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SAVACassava Sciences,… | AVXLAnavex Life Scien… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 1.51x |
| 52-Week HighHighest price in past year | $4.98 | $13.99 |
| 52-Week LowLowest price in past year | $1.51 | $2.61 |
| % of 52W HighCurrent price vs 52-week peak | +39.3% | +22.3% |
| RSI (14)Momentum oscillator 0–100 | 46.8 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 712K | 1.4M |
Evenly matched — SAVA and AVXL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SAVA as "Buy" and AVXL as "Buy".
| Metric | SAVACassava Sciences,… | AVXLAnavex Life Scien… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $11.00 |
| # AnalystsCovering analysts | 12 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SAVA leads in 2 of 6 categories (Income & Cash Flow, Total Returns). AVXL leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallCassava Sciences, Inc. (SAVA)Leads 2 of 6 categories
Loading custom metrics...
SAVA vs AVXL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SAVA or AVXL a better buy right now?
Analysts rate Cassava Sciences, Inc.
(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SAVA or AVXL?
Over the past 5 years, Cassava Sciences, Inc.
(SAVA) delivered a total return of -67. 0%, compared to -72. 4% for Anavex Life Sciences Corp. (AVXL). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus AVXL's -25. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SAVA or AVXL?
By beta (market sensitivity over 5 years), Anavex Life Sciences Corp.
(AVXL) is the lower-risk stock at 1. 51β versus Cassava Sciences, Inc. 's 2. 02β — meaning SAVA is approximately 34% more volatile than AVXL relative to the S&P 500.
04Which is growing faster — SAVA or AVXL?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to -3. 8% for Anavex Life Sciences Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SAVA or AVXL?
Cassava Sciences, Inc.
(SAVA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Anavex Life Sciences Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SAVA leads at 0. 0% versus 0. 0% for AVXL. At the gross margin level — before operating expenses — SAVA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SAVA or AVXL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SAVA or AVXL better for a retirement portfolio?
For long-horizon retirement investors, Anavex Life Sciences Corp.
(AVXL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cassava Sciences, Inc. (SAVA) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVXL: -25. 7%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SAVA and AVXL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.